3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
5
Completed
5
Recruiting
3
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Acute
2
Leukemia
2
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Mastocytosis, Systemic
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Gastrointestinal Stromal Tumors
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Dasatinib
×
Clear all
NCT02015728
2016-12-15
SEED
Seattle Children's Hospital
Phase NA
Unknown
20 enrolled